TNGX FY2025 EPS Estimate Lowered by Cantor Fitzgerald

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Stock analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for Tango Therapeutics in a report issued on Monday, March 10th. Cantor Fitzgerald analyst E. Schmidt now expects that the company will earn ($1.48) per share for the year, down from their previous estimate of ($1.39). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.19) per share.

Tango Therapeutics (NASDAQ:TNGX) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%. The company had revenue of $4.12 million during the quarter, compared to the consensus estimate of $7.84 million.

Tango Therapeutics Price Performance

Tango Therapeutics stock opened at $1.85 on Wednesday. Tango Therapeutics has a one year low of $1.72 and a one year high of $12.02. The firm has a market capitalization of $200.00 million, a P/E ratio of -1.57 and a beta of 0.87. The business has a fifty day moving average price of $2.70 and a 200-day moving average price of $4.86.

Insider Buying and Selling

In other Tango Therapeutics news, CEO Barbara Weber sold 9,778 shares of the firm’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $2.99, for a total transaction of $29,236.22. Following the sale, the chief executive officer now owns 1,631,264 shares in the company, valued at $4,877,479.36. This trade represents a 0.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last quarter, insiders have sold 24,268 shares of company stock worth $72,561. Corporate insiders own 6.30% of the company’s stock.

Institutional Trading of Tango Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. TCG Crossover Management LLC bought a new position in shares of Tango Therapeutics during the 4th quarter valued at $33,174,000. Boxer Capital Management LLC purchased a new position in Tango Therapeutics in the fourth quarter worth about $32,077,000. Gilead Sciences Inc. purchased a new position in Tango Therapeutics in the fourth quarter worth about $15,000,000. Farallon Capital Management LLC bought a new stake in Tango Therapeutics in the fourth quarter worth about $12,360,000. Finally, Nantahala Capital Management LLC bought a new stake in shares of Tango Therapeutics during the fourth quarter valued at approximately $8,666,000. Hedge funds and other institutional investors own 78.99% of the company’s stock.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.